PVP-037.2 

PVP-037.2 is a TLR7/8 agonist. PVP-037.2 can serve as an adjuvant to enhance vaccine-induced T_H1 type immune responses, increasing the production of antigen-specific antibodies IgG1 and IgG2c^[1].

PVP-037.2 (0.1-100 μM，24 h) induces concentration-dependent production of TNF and IL-1β in human elder peripheral blood mononuclear cells (PBMCs)^[1].
PVP-037.2 ((100 μM，20-24 h) demonstrates a TLR7/8-dependent immunomodulatory profile^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

PVP-037.2 (3 mg/kg, i.v., measured 0-8 hours post-administration) shows high plasma clearance and almost no hemolytic activity in adult C57BL/6J mice (20 to 30 g in weight)^[1].
PVP-037.2 (100 nmol per mouse, i.v., single immunization) exhibits potent adjuvant effects in C57BL/6J mice immunized with the trivalent recombinant rHA influenza vaccine Flublok and SARS-CoV-2 spike protein^[1].
Compared with the use of PVP-037.2 alone, the PVP-037.2 O/W emulsion formulation (10 nmol per mouse, i.v., IgG titer measured on day 42) enhances the innate immune activation capability in wild-type C57BL/6J mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

439.43

C₂₃H₂₀F₃N₅O

CC1=CN2C=C(N=C2N=C1)C3=CC(NC(C4=C(C=C(C=C4)CN)C(F)(F)F)=O)=C(C=C3)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Soni D, et al. From hit to vial: Precision discovery and development of an imidazopyrimidine TLR7/8 agonist adjuvant formulation[J]. Science Advances, 2024, 10(27): eadg3747.  [Content Brief]